Caladrius Biosciences, Inc. (NASDAQ:CLBS)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Friday. They presently have a $7.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 132.56% from the stock’s current price.
Other equities research analysts also recently issued research reports about the company. Zacks Investment Research downgraded Caladrius Biosciences from a “buy” rating to a “hold” rating in a report on Monday, September 25th. ValuEngine raised Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st.
Shares of Caladrius Biosciences (NASDAQ CLBS) opened at $3.01 on Friday. Caladrius Biosciences has a twelve month low of $2.63 and a twelve month high of $7.79.
Caladrius Biosciences (NASDAQ:CLBS) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative return on equity of 141.14% and a negative net margin of 84.10%. research analysts forecast that Caladrius Biosciences will post -2.73 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Caladrius Biosciences, Inc. (CLBS) Stock Rating Reaffirmed by HC Wainwright” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/12/caladrius-biosciences-inc-clbs-stock-rating-reaffirmed-by-hc-wainwright.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Caladrius Biosciences by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock valued at $723,000 after acquiring an additional 4,163 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Caladrius Biosciences by 34.3% during the 1st quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock valued at $491,000 after acquiring an additional 24,900 shares in the last quarter. Finally, KCG Holdings Inc. boosted its holdings in shares of Caladrius Biosciences by 74.6% during the 1st quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 15,501 shares in the last quarter. 6.47% of the stock is currently owned by institutional investors.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.